SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as investors grapple with extreme volatility in the semiconductor sector, driven by ongoing geopolitical tensions in the Middle East and concerns over potential supply chain disruptions. The community is actively debating whether to treat recent price fluctuations as a genuine trend reversal or a temporary 'dead cat bounce,' with many traders highlighting the risks of holding leveraged ETFs amid contradictory reports regarding ceasefire agreements and chip sector valuations.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors monitor ongoing discussions regarding strategic mineral assets in Greenland and speculate on potential positive catalysts following recent metallurgical test results and pilot plant developments. The community remains highly focused on the company's long-term potential in the heavy rare earth sector while debating the impact of management's communications and the timing of a revised bankable feasibility study.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors weigh the stock's role as a defensive hedge against ongoing market volatility and geopolitical concerns, while debate intensifies over the company's massive cash pile and the impact of the leadership transition on future growth strategies. Community members are actively split, with some praising the firm's fiscal discipline and fortress balance sheet, while others voice frustration over stagnant performance compared to broader market rallies and the lack of shareholder returns.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is currently at the center of significant market speculation as investors digest a recent $60 million at-the-market equity offering alongside a push into high-growth AI and silicon photonics markets. While the community remains deeply divided, with some critics pointing to the dilutive impact and high valuation relative to trailing revenue, bulls are actively focused on the company's strong order backlog and potential for massive follow-on contracts with major hyperscale customers.

Maulcoin

Maulcoin is trending as a highly active community-driven memecoin project, with members rallying to maintain its visibility despite technical hurdles with ticker and chart integration. Investors are actively debating the coin's long-term sustainability while leveraging social media raids and decentralized exchange platforms to push for wider adoption.

Applied Digital Corporation

Applied Digital is trending as investors await a critical earnings report, with community focus heavily split between anticipation of major hyperscaler lease announcements and skepticism regarding the company's debt management and project timelines. Shareholders are particularly sensitive to any updates on the April 18th lease execution deadline, viewing the call as a pivotal moment for management to prove their ability to convert massive infrastructure expansion into realized revenue.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

Aircoin is trending as a community-driven project on Solana, drawing attention for its long-term focus, voluntary supply locks via its "Airlock" system, and a dedicated holder base that emphasizes consistent building over short-term hype. Investors are actively highlighting the project's deep narrative roots, active treasury, and persistent community engagement as key differentiators in the broader memecoin market.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending due to the FDA's acceptance of its BLA resubmission for RP1 in advanced melanoma, with investors eyeing the April 10, 2026 PDUFA date. The community remains deeply divided, with some betting on a successful approval after management addressed previous regulatory hurdles, while others caution that the lack of new clinical data makes a second rejection a significant risk.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors digest the recent leadership transition in R&D and intensified pressure from top shareholder Shah Capital, who is demanding strategic overhauls and improved accountability. The community remains deeply divided, with many expressing frustration over persistent price volatility and a lack of clear communication from management regarding partnership timelines for their core vaccine assets.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 Corp is experiencing significant investor interest driven by its strategic pivot toward high-margin AI data center infrastructure and a high-profile, Google-backed expansion deal. While the community is actively debating the company's valuation and the reliability of its AI-focused business model compared to traditional Bitcoin mining, technical traders are closely monitoring intense volatility and active options trading as the stock navigates key support and resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July.</li><li>Following months of engagement between the company and the FDA, Replimune subsequently resubmitted its application in October with additional information, data and analyses.</li><li>RP1 is Replimune’s lead product candidate.</li></ul>Shares of Replimune Group Inc (REPL) fell 15% on Wednesday as the deadline for the U.S. Food and Drug Administration’s decision on its skin cancer therapy RP1 draws close.If losses hold, REPL is on track for its worst session in nearly seven months.The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10. RP1 is Replimune’s lead product candidate.<h2 class="st-heading-2">RP1’s Past Issues</h2>In late July 2025, the FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency said in the letter that it is unable to approve the application in its present form, and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.Following months of engagement between the company and the FDA, Replimune subsequently resubmitted its application in October with additional information, data, and analyses.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REPL stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at extremely high levels. Retail chatter around the stock has increased 171% over the past seven days, Stocktwits data showed.A retail user said that the FDA might ask for a fresh trial for approval, pitching the chances for a green light from the agency at below 20%.<stembedurl>https://www.stocktwits.com/BioRocket/message/649736736</stembedurl>Yet another user dismissed concerns about trial design.<stembedurl>https://www.stocktwits.com/pblegend66/message/649729070</stembedurl>Another user opined that the stock can either triple or wipe out a majority of its value after the FDA decision.<stembedurl>https://www.stocktwits.com/LilJimmy007/message/649726397</stembedurl><a href="https://stocktwits.com/symbol/REPL">REPL stock</a> has fallen 7% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/tron-taps-86-billion-stablecoin-liquidity-via-hyperlane-across-150-chains-after-justin-sun-s-ai-push/cZJf39TRIAk">TRON Taps $86 Billion Stablecoin Liquidity Via Hyperlane Across 150 Chains, After Justin Sun’s AI Push</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug

The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10.

Equity

The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10.


Replimune Group (NASDAQ:REPL) Stock Price Down 6.7% Following Insider Selling

Replimune Group (NASDAQ:REPL) Shares Down 6.7% After Insider Selling...

Christopher Sarchi Sells 6,500 Shares of Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) insider Christopher Sarchi sold 6,500 shares of the company's stock in a transaction on Thursday, April 2nd. The stock was sold at an average...

Replimune Group (NASDAQ:REPL) Insider Christopher Sarchi Sells 6,500 Shares

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) insider Christopher Sarchi sold 6,500 shares of the firm's stock in a transaction on Thursday, April 2nd. The shares were sold at an average...

<ul class="summary-bullets"><li>The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July.</li><li>Following months of engagement between the company and the FDA, the company subsequently resubmitted its application in October with additional information, data and analyses.</li></ul> Shares of Replimune Group Inc (REPL) closed 11% higher on Thursday as the deadline for the U.S. Food and Drug Administration’s decision on its skin cancer therapy RP1 draws close.The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10. RP1 is Replimune’s lead product candidate.<h2 class="st-heading-2">RP1’s Past Issues</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/replimune-sarepta-capricor-stocks-surge-after-vinay-prasad-fda-exit/choXJLOR5Cg">issued</a> a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July.The agency said in the letter that it is unable to approve the application in its present form and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.Following months of engagement between the company and the FDA, the company subsequently resubmitted its application in October with additional information, data and analyses.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REPL stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that shareholders are setting up to be disappointed like the last time when RP1 was denied approval.<stembedurl>https://www.stocktwits.com/TopCharts/message/649353360</stembedurl>Yet another expressed doubts about the FDA approving the drug, opining that a fresh trial would be needed for the same.<stembedurl>https://www.stocktwits.com/Steve_TheBull_Rogers/message/649347582</stembedurl>According to data from Koyfin, five of the seven analysts covering REPL stock rate it ‘Buy’ or higher while two rate it a ‘Hold’. The 12-month average price target on the stock is $12.86, representing a potential upside of about 53%. &nbsp;<a href="https://stocktwits.com/symbol/REPL">REPL stock</a> has fallen 2% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-sbac-stock-rallying-today/cZ7UR5SRI8r">Why Is SBAC Stock Rallying Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Rallies In Anticipation Of FDA Decision On Skin Cancer Drug

Replimune Group (NASDAQ:REPL) Shares Up 7.2% - Should You Buy?

Replimune Group (NASDAQ:REPL) Trading Up 7.2% - Time to Buy...

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.

Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Hold" by Analysts

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has been given an average recommendation of "Hold" by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two...

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Corcept jumps after FDA approves Lifyorli combo for platinum-resistant ovarian cancer, marking the first-of-its-kind treatment.

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.

Patrick OShaughnessy - @patrick_oshag on X

Citrini - @Citrini7 on X

Bucco Capital - @buccocapital on X

Joe Weisenthal - @TheStalwart on X

The must-watch individual or show that brings entertainment to finance. This award celebrates the content you look forward to daily - bringing a sharp market edge to engaging discussions. 

Stocktwits

Stocktwits Polls

Traders are intensely monitoring the April 10th FDA decision for signs of an impending CRL or breakthrough approval.

Investors are weighing the high-stakes potential for a 200% move up against the threat of a complete collapse toward $2-3.

Significant volume spikes and price weakness have fueled rumors that institutional insiders may have leaked the upcoming regulatory news.

Bears argue the trial design deficiencies that led to a previous rejection remain unaddressed, making approval unlikely.

Current Price	$5.89
Prev Close	$7.80
Open	$8.05
Dividend Yield	0.00%
50-Day Moving Average	$7.56
Beta	0.82
Avg. Volume	1.63M
PE Ratio	-1.64

52-Week High	$13.24
52-Week Low	$2.68
Market Capitalization	$644.07M
EPS (Annual)	-$3.07
Price to Book	2.23
Revenue Per Employee	$0.00

REPL
Replimune Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest REPL News

REPLReplimune Group Inc